Evergreen Wealth Management LLC Sells 808 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Evergreen Wealth Management LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,628 shares of the biopharmaceutical company’s stock after selling 808 shares during the period. Regeneron Pharmaceuticals accounts for approximately 2.8% of Evergreen Wealth Management LLC’s investment portfolio, making the stock its 15th biggest holding. Evergreen Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $5,414,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. PGGM Investments raised its stake in Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after purchasing an additional 51,900 shares in the last quarter. Osaic Holdings Inc. grew its position in shares of Regeneron Pharmaceuticals by 55.2% during the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after purchasing an additional 6,073 shares in the last quarter. Generate Investment Management Ltd bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $6,300,000. Hudson Value Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $398,000. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock valued at $67,969,000 after buying an additional 73,176 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $762.65 on Tuesday. The business has a fifty day simple moving average of $756.55 and a 200 day simple moving average of $645.80. The company has a market cap of $80.15 billion, a P/E ratio of 18.26, a P/E/G ratio of 1.96 and a beta of 0.39. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $12.46 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 8,431 shares of company stock worth $5,733,521. Insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on REGN shares. Evercore ISI raised their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Finally, UBS Group increased their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $784.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.